208 related articles for article (PubMed ID: 38227370)
1. APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.
Datta S; Antonio BM; Zahler NH; Theile JW; Krafte D; Zhang H; Rosenberg PB; Chaves AB; Muoio DM; Zhang G; Silas D; Li G; Soldano K; Nystrom S; Ferreira D; Miller SE; Bain JR; Muehlbauer MJ; Ilkayeva O; Becker TC; Hohmeier HE; Newgard CB; Olabisi OA
J Clin Invest; 2024 Jan; 134(5):. PubMed ID: 38227370
[TBL] [Abstract][Full Text] [Related]
2. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.
Olabisi OA; Zhang JY; VerPlank L; Zahler N; DiBartolo S; Heneghan JF; Schlöndorff JS; Suh JH; Yan P; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):830-7. PubMed ID: 26699492
[TBL] [Abstract][Full Text] [Related]
3. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression.
Gupta N; Waas B; Austin D; De Mazière AM; Kujala P; Stockwell AD; Li T; Yaspan BL; Klumperman J; Scales SJ
Sci Rep; 2024 Feb; 14(1):3765. PubMed ID: 38355600
[TBL] [Abstract][Full Text] [Related]
5. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
[TBL] [Abstract][Full Text] [Related]
6. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.
Vandorpe DH; Heneghan JF; Waitzman JS; McCarthy GM; Blasio A; Magraner JM; Donovan OG; Schaller LB; Shah SS; Subramanian B; Riella CV; Friedman DJ; Pollak MR; Alper SL
Pflugers Arch; 2023 Mar; 475(3):323-341. PubMed ID: 36449077
[TBL] [Abstract][Full Text] [Related]
8. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
[TBL] [Abstract][Full Text] [Related]
9. Variant APOL1 protein in plasma associates with larger particles in humans and mouse models of kidney injury.
Andrews M; Yoshida T; Henderson CM; Pflaum H; McGregor A; Lieberman JA; de Boer IH; Vaisar T; Himmelfarb J; Kestenbaum B; Chung JY; Hewitt SM; Santo BA; Ginley B; Sarder P; Rosenberg AZ; Murakami T; Kopp JB; Kuklenyik Z; Hoofnagle AN
PLoS One; 2022; 17(10):e0276649. PubMed ID: 36279295
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes.
Scales SJ; Gupta N; De Mazière AM; Posthuma G; Chiu CP; Pierce AA; Hötzel K; Tao J; Foreman O; Koukos G; Oltrabella F; Klumperman J; Lin W; Peterson AS
J Am Soc Nephrol; 2020 Sep; 31(9):2044-2064. PubMed ID: 32764142
[TBL] [Abstract][Full Text] [Related]
11. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.
McCarthy GM; Blasio A; Donovan OG; Schaller LB; Bock-Hughes A; Magraner JM; Suh JH; Tattersfield CF; Stillman IE; Shah SS; Zsengeller ZK; Subramanian B; Friedman DJ; Pollak MR
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34350953
[TBL] [Abstract][Full Text] [Related]
12. APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice.
Ryu JH; Ge M; Merscher S; Rosenberg AZ; Desante M; Roshanravan H; Okamoto K; Shin MK; Hoek M; Fornoni A; Kopp JB
PLoS One; 2019; 14(4):e0211559. PubMed ID: 30998685
[TBL] [Abstract][Full Text] [Related]
13. DGAT2 Inhibition Potentiates Lipid Droplet Formation To Reduce Cytotoxicity in APOL1 Kidney Risk Variants.
Chun J; Riella CV; Chung H; Shah SS; Wang M; Magraner JM; Ribas GT; Ribas HT; Zhang JY; Alper SL; Friedman DJ; Pollak MR
J Am Soc Nephrol; 2022 May; 33(5):889-907. PubMed ID: 35232775
[TBL] [Abstract][Full Text] [Related]
14. The key role of NLRP3 and STING in APOL1-associated podocytopathy.
Wu J; Raman A; Coffey NJ; Sheng X; Wahba J; Seasock MJ; Ma Z; Beckerman P; Laczkó D; Palmer MB; Kopp JB; Kuo JJ; Pullen SS; Boustany-Kari CM; Linkermann A; Susztak K
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651582
[TBL] [Abstract][Full Text] [Related]
15. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
[TBL] [Abstract][Full Text] [Related]
16. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
17. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
Ekulu PM; Adebayo OC; Decuypere JP; Bellucci L; Elmonem MA; Nkoy AB; Mekahli D; Bussolati B; van den Heuvel LP; Arcolino FO; Levtchenko EN
Cells; 2021 Jul; 10(8):. PubMed ID: 34440683
[TBL] [Abstract][Full Text] [Related]
18. From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?
Olabisi O; Al-Romaih K; Henderson J; Tomar R; Drummond I; MacRae C; Pollak M
Clin Nephrol; 2016 Supplement 1; 86 (2016)(13):114-118. PubMed ID: 27509583
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice.
Aghajan M; Booten SL; Althage M; Hart CE; Ericsson A; Maxvall I; Ochaba J; Menschik-Lundin A; Hartleib J; Kuntz S; Gattis D; Ahlström C; Watt AT; Engelhardt JA; Monia BP; Magnone MC; Guo S
JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217349
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.
Yang YW; Poudel B; Frederick J; Dhillon P; Shrestha R; Ma Z; Wu J; Okamoto K; Kopp JB; Booten SL; Gattis D; Watt AT; Palmer M; Aghajan M; Susztak K
Mol Ther; 2022 Jul; 30(7):2491-2504. PubMed ID: 35450819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
